TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25264753
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg)
Study: 23450513
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sildenafil, 3 times per day for 9 weeks
Study: 16757158
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg once a day for 5 days
Study: 8440860
Drug: Multi-nutrient supplementation
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient supplementation with a 360-kcal high carbohydrate, low fat liquid supplement every day
Study: 8440860
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high intensity progressive resistance training and multi-nutrient supplementation
Study: 22718030
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein 0 g (Control)
Study: 22718030
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein 10 g
Study: 22718030
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein 20 g
Study: 22718030
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein 30 g
Study: 12950521
Drug: Combined antiplatelet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiplatelet therapy
Study: 12950521
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy with warfarin
Study: 1906161
Drug: Tobramycin administered
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin administered every 6 hours
Study: 1906161
Drug: Tobramycin administered
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin administered every 8 hours
Study: 6504709
Drug: Indacrinone enantiomers
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone enantiomers (‐2.5/+80 mg)
Study: 6504709
Drug: Indacrinone enantiomers
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone enantiomers (‐5/+80 mg)
Study: 6504709
Drug: Indacrinone enantiomers
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone enantiomers (‐10/+80 mg)
Study: 30020447
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of oral azithromycin (A3)
Study: 30020447
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of oral doxycycline (D3)
Study: 30020447
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of oral doxycycline (D7)
Study: 30043524
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 2.0 mg
Study: 30043524
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment regimens
Study: 26807718
Drug: Anti-oxidative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidative therapy (pravastatin 40 mg/d and vitamin E 300 mg/d)
Study: 24972936
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (antibiotherapy + nasal decongestant) (2 weeks)
Study: 20682669
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) 4.5 g/night
Study: 20682669
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) 6 g/night
Study: 17435611
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (FS) (120 mg elemental iron)
Study: 15590762
Drug: Theophylline (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (loading dose of 4 mg/kg IV over 30 min, followed by 0.4 mg/kg/min for at least 6 hours, then 350 mg orally three times daily for 4 days)
Study: 15590762
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered in control arm)
Study: 14565810
Drug: Sulfonylureas (tolazamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas (tolazamide, glyburide, glipizide GITS, glimepiride) with insulin
Study: 14565810
Drug: Glimepiride with
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride with insulin
Study: 14565810
Drug: Sulfonylureas with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas with insulin
Study: 10395630
Drug: Atorvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 80 mg per day
Study: 8908821
Drug: Amiodarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (400 mg/day for one month, then 200 mg/day)
Study: 1909085
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (2 L daily of 3.5% crystalline amino acids in 5% dextrose) plus standard therapy
Study: 1909085
Drug: Oxandrolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (20 mg orally four times a day) plus standard therapy
Study: 1909085
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxandrolone and nutritional supplementation plus standard therapy
Study: 1909085
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (abstinence, balanced diet, multivitamins)
Study: 31981558
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (approximately 20 mg per kg of bodyweight)
Study: 17926822
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg/day for treatment-naive patients, 1 mg/day for patients with lamivudine failure)
Study: 11782044
Drug: Mean of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean of the other group or counted as treatment failures after dichotomization of the endpoint
Study: 9289526
Drug: Nabumetone (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1-2 g once a day)
Study: 9289526
Drug: Aceclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (100 mg two times each day)
Study: 8295814
Drug: Clarithromycin oral
Normalized name: clarithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin oral suspension (7.5 mg/kg; maximum, 500 mg)
Study: 8295814
Drug: Cefaclor oral
Normalized name: cefaclor Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor oral suspension (20 mg/kg; maximum, 500 mg)
Study: 27623561
Drug: STOP Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOP Protocol (combination of risk stratification with TCD and selective chronic red cell transfusion)
Study: 24662777
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day, n = 24)
Study: 24662777
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day, n = 24)
Study: 20525999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ezetimibe and Simvastatin (n = 24)
Study: 20525999
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Ezetimibe + Simvastatin)
Study: 16356293
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the DRP program with psychiatric consultation (PC+DRP, n=39)
Study: 16356293
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with brief cognitive behavior therapy (CBT+DRP, n=44)
Study: 12727966
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d) with N(G)-monomethyl-L-arginine infusion
Study: 1317910
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Chlorthalidone + Clonidine)
Study: 3937815
Drug: Semi‐Euglucon N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi‐Euglucon N 1.75 mg
Study: 3937815
Drug: Daonil N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daonil N 1.75 mg
Study: 3937815
Drug: Semi‐Euglucon 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi‐Euglucon 2.5 mg
Study: 3937815
Drug: Daonil 2.5
Normalized name: Semi-Daonil 2.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daonil 2.5 mg
Study: 3937815
Drug: Both HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both HB 420 preparations
Study: 3937815
Drug: Both HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both HB 419 preparations
Study: 3937815
Drug: HB 420
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 420 preparations
Study: 3937815
Drug: Other HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other HB 419 preparation
Study: 27293194
Drug: Voxtalisib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib (50 mg BID) in combination with rituximab
Study: 27293194
Drug: Voxtalisib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib (50 mg BID) in combination with rituximab+bendamustine
Study: 25922233
Drug: Aprepitant group
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant group (5-HT3-receptor antagonist + dexamethasone + aprepitant or fosaprepitant)
Study: 25922233
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5-HT3-receptor antagonist + dexamethasone)
Study: 20886400
Drug: Fluoroscopy during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy during oral double-balloon enteroscopy (DBE)
Study: 20886400
Drug: Nonfluoroscopy during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfluoroscopy during oral double-balloon enteroscopy (DBE)
Study: 1833900
Drug: Enoximone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1 mg/kg bw)
Study: 1833900
Drug: Enoximone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1.5 mg/kg bw)
Study: 1833900
Drug: Phosphodiesterase inhibitors
Normalized name: Phosphodiesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase inhibitors (general)
Study: 6213379
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin 1.5 percent solution
Study: 6213379
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin phosphate 1.0 percent solution
Study: 30954433
Drug: Human Growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Growth Hormone (HGH)
Study: 22980373
Drug: Lisinopril 10mg
Normalized name: LISINOPRIL 10MG TAB
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril 10mg
Study: 19578247
Drug: Once-daily LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily LPV/r 460/115 mg/m(2) plus two NRTIs
Study: 19578247
Drug: Twice-daily LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily LPV/r 230/57.5 mg/m(2) plus two NRTIs
Study: 15001452
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg daily for the initial 8 weeks, then doubled for the remainder of the study
Study: 24760603
Drug: Timolol 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.1% gel
Study: 11738915
Drug: Curettage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curettage of the entire anterior capsule (Group A)
Study: 11738915
Drug: Curettage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curettage of the nasal half of the anterior capsule (Group B)
Study: 8519047
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg TID orally for 3 months
Study: 8519047
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg TID orally for 6 months
Study: 3459860
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel used twice a day
Study: 29273232
Drug: Water resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water resistance therapy
Study: 22813225
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) varnish or solution (Treatment A)
Study: 22813225
Drug: Titanium tetrafluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium tetrafluoride (TiF(4)) varnish or solution (Treatment B)
Study: 22813225
Drug: Placebo varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo varnish or no treatment (Treatment C)
Study: 22813225
Drug: Titanium tetrafluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium tetrafluoride (TiF(4)) formulations
Study: 15693825
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C gum (60 mg, Series I)
Study: 15693825
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C + carbamide gum (30 mg + 30 mg, Series II)
Study: 15693825
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C + carbamide gum (30 mg + 30 mg)
Study: 15693825
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C gum (30 mg)
Study: 12622502
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 mg)‐propofol mixture
Study: 8624083
Drug: AF102B (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF102B (40 mg, tid, po)
Study: 8624083
Drug: AF102B (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF102B (60 mg, tid, po)
Study: 1760811
Drug: 6 x
Normalized name: Mepilex AG 6 x 6"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 x 10(6) IU or 12 x 10(6) IU Cetus IL-2/m2 by i.v. bolus daily for 5 consecutive days on weeks 1, 3 and 5
Study: 15195895
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 750 mg daily
Study: 590600
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g single dose for 3 days)
Study: 590600
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 g single dose for 3 days)
Study: 26501007
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (500mg orally one hour prior to extraction and 160mg gel foam soaked in tranexamic acid placed into the extraction socket postoperatively)
Study: 26501007
Drug: Placebo (crocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (crocin orally one hour prior to extraction and gel foam soaked in saline placed into the extraction socket postoperatively)
Study: 21866716
Drug: Group psychoeducational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychoeducational music therapy songwriting session concerning coping skills
Study: 9295241
Drug: 0.3% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% tacrolimus ointment
Study: 3524226
Drug: Computer-assisted insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-assisted insulin dosage decision-making (n = 7)
Study: 3524226
Drug: Standard algorithms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard algorithms for insulin adjustment (n = 9)
Study: 28524639
Drug: IVPM (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVPM (1000 mg methylprednisolone)
Study: 22999634
Drug: Prompt laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt laser treatment
Study: 22999634
Drug: Deferred laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred laser treatment
Study: 23819587
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Agents (CHA) introduced as part of health systems strengthening and referral improvement.
Study: 23819587
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Agents (CHA) with supervisory systems, information and monitoring operations, and logistics support.
Study: 19309251
Drug: Pioglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone plus metformin (15 mg/day for 12 weeks, then increased to 30 mg/day for 16 weeks)
Study: 19309251
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (500 or 750 mg/day)
Study: 11775087
Drug: Pharmacotherapy (antidepressants)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (antidepressants)
Study: 11775087
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (pharmacotherapy with psychotherapy or electroconvulsive therapy)
Study: 25491597
Drug: LCI699 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 0.5 mg
Study: 25491597
Drug: LCI699 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (doses > 1 mg)
Study: 22406775
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg/day for 5 days
Study: 22406775
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B capsules)
Study: 11282811
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (25-75 mg, flexible dose)
Study: 9788003
Drug: Disulfiram 250
Normalized name: disulfiram 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 250 mg/day
Study: 30807767
Drug: Plasma homocysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma homocysteine concentrations at the study median of 8.0 μmol/L
Study: 24303415
Drug: Combined intratympanic
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined intratympanic and systemic steroid therapy
Study: 24303415
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid therapy alone
Study: 15110197
Drug: Percutaneous myocardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous myocardial laser revascularization (PMLR) with optimal medical therapy (n = 40)
Study: 15110197
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure with optimal medical therapy (n = 42)
Study: 7924366
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 1000 mL i.v. Ringer's acetate solution during a 40‐min period
Study: 7924366
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (without infusion)
Study: 28213121
Drug: Vortioxetine 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10/20 mg QD (flexible)
Study: 25229836
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) therapy for 10 min
Study: 15718041
Drug: GM1 ganglioside
Normalized name: Porcine GM1 ganglioside
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 ganglioside administration to AD fibroblasts
Study: 9988392
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (1,000-1,500 IU IM) and FSH (75-100 IU SC) administered every alternate day until puberty and spermatogenesis achieved
Study: 2121564
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg cyclandelate
Study: 2121564
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cyclandelate twice daily for 14 days
Study: 16733865
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same administration schedule as trial group)
Study: 11227239
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant Erythropoietin (r‐EPO) administered three times per week for four weeks
Study: 11227239
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times per week for four weeks
Study: 9355712
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis (PD) with Verapamil added intraperitoneally at a dose of 10 mg/L/cycle for 36 hours
Study: 3896279
Drug: Nicardipine (10‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (10‐30 mg three times a day, mean dose 69.4 mg per day)
Study: 30536161
Drug: Mineral-rich solution
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral-rich solution